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The brain contains two main polyunsaturated fatty acids (PUFA), arachidonic acid (AA) and docosahexaenoic 
acid (DHA). These PUFA are located almost exclusively in the sn2-position of phosphoglycerides which are 
found in the neural cell membranes. Liberation of these PUFA from the phosphoglycerides occurs via the ac-
tion of specific phospholipases (PLA2). Free AA can be metabolised by cyclooxygenases to prostaglandins and 
thromboxane, while both AA and DHA can be metabolised by lipoxygenases to form hydroxy derivatives and 
leukotrienes. AA is also metabolised to lipoxins via the 5-lipoxygenase pathway.  The eicosanoids formed play 
important roles in neural function including sleep induction (PGD2), long term potentiation, spatial learning and 
synaptic plasticity (PGE2), resolution of inflammation (lipoxins) and anti-inflammatory and neuroprotective 
bioactivity (dihydroxy-docosatriene, neuroprotectin D1, formed from DHA). COX-inhibitors have been shown 
to reduce oxidative stress and cognitive impairment. Additionally, drugs which are used to treat depression 
have been shown to reduce the turnover of AA to PGE2 in the brain. Diets deficient in omega 3 PUFA lead to 
reduced DHA in the brain and increased turnover of AA to eicosanoids, an effect which is overcome by restor-
ing the omega 3 PUFA to the diet. In neural trauma and neurodegenerative diseases, there is a dramatic rise in 
the levels of AA-derived eicosanoids. In contrast, DHA-derived compounds can prevent neuroinflammation. 
Clearly, the eicosanoids are very important for the normal functioning of the brain, while the PUFA themselves 
are important in membrane structure and function.  
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INTRODUCTION  
The brain has the second highest content of lipids in the 
human body next to adipocytes, at 36-60%. Brain lipids are 
far more complex than adipose lipids and consist of glyc-
erophospholipids, sphingolipids, gangliosides and choles-
terol, with little or no triglycerides and cholesterol esters. 
Metabolites of the glycerophospholipid polyunsaturated 
fatty acids (PUFA) have been implicated in neuroinflam-
mation and depression. Glycerophospholipids are com-
posed of two fatty acids attached to a glycerol backbone. A 
saturated fatty acid is usually found in the sn-1 position and 
a PUFA in the sn-2 position and a phosphate in the sn-3 
position, covalently linked to a base group (choline, serine, 
inositol, ethanolamine). The main brain PUFA are arachi-
donic acid (AA; 20:4ω6) or docosa-hexaenoic acid (DHA; 
22:6ω3); these are both derived from the essential fatty 
acids (EFA), linoleic (LA) and alpha-linolenic acids (ALA), 
respectively. In grey matter, the proportion of DHA in 
glycerophospholipids is higher than AA, whereas in white 
matter this situation is reversed.1 The brain grey matter 
PUFA profiles are similar in different mammals, with DHA, 
AA and 22:4n–6 being the three major PUFA (Fig. 1).2 
    It has been well documented that the fatty acid composi-
tion of adipose tissue in a healthy individual is indicative of 
the fatty acid composition of lipids in their diet. This is also 
true for brain fatty acid composition, however there are 
major differences between these two tissues. Adipose lipids 
are mostly triglycerides and contain very low levels of AA 
and DHA; brain lipids are mostly complex lipids and con-
tain high proportions of these two long chain PUFA in the 
neural cell membranes. Furthermore, it is very difficult, but 
not impossible, to alter the fatty acid profile of the brain 
cell membranes; the brain DHA levels can be decreased by 
a dietary deficiency of omega 3 PUFA and brain AA and 
DHA levels are both decreased in dietary EFA deficiency.3 
The effect of omega 3 PUFA deficiency on the brain has 
been far more extensively characterised than that of EFA 
deficiency. Most importantly deficiency of brain DHA has 
critical effects on neuronal development and behaviour, 
including changes in learning, memory, auditory and olfac-
tory responses. Brain DHA plays a crucial role in [a] mem-
brane order (membrane fluidity);4,5 [b] regulation of dopa-
minergic and serotoninergic neurotransmission;6 [c] regula-
tion of membrane-bound enzymes (Na/K-dependent 
ATP’ase);7 [d] signal transduction via effects on inositol 
phosphates, diacylglycerol and protein kinase C;8 [e]  
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decreased glucose uptake;9,10 [f] regulation of the synthe-
sis of eicosanoids derived from arachidonic acid,11 and as 
a precursor of docosatrienes and 17S resolvins,12 novel 
anti-inflammatory mediators;13 [g] involvement in the 
growth of neuronal cells and the protection of cells from 
apoptosis14-17 and [h] regulation of gene expression of 
many different genes in rat brain (for review see, Sinclair 
et al 2002).18 There has been far less research on the role 
of brain AA, partly because it is almost impossible to de-
plete brain AA levels by dietary deficiency studies. 
Clearly, brain AA is important as a precursor of a wide 
range of eicosanoids and leukotrienes which play critical 
roles in many aspects of neural function, as will be seen 
in this review. 
    Under the control of specific stimuli, PUFA are re-
leased from the glycerophospholipids by the action of 
various phospholipases (cytosolic phospholipase AII, 
cPLA2; plasmalogen selective phospholipase AII, PlsEtn-
PLA2 and secretory phospholipase AII, sPLA2)19 and me-
tabolised by cyclooxygenase (COX) and lipoxygenase 
(LOX) enzymes into a variety of oxygenated PUFA de-
rivatives known as eicosanoids (prostaglandins, throm-
boxanes, lipoxins, leukotrienes, hydroxyeicosatetraenoic 
and epoxyeicosatetraenoic acids), and docosatrienes (neu-
roprotectins and resolvins) which are locally acting hor-
mone-like compounds as shown in Figure 2. As discussed 
later, COX is involved in the production of pro-
inflammatory metabolites of AA, including prostagland-
ins and thromboxanes and leukotrienes (from AA via the 
LOX pathway). LOX on the other hand generates anti-
inflammatory DHA-derived metabolites and lipoxins de-
rived from AA via the 5-LOX pathway (Fig. 2). COX-1 is 
constitutively expressed in the body and acts as a “house-
keeping” enzyme.19,20 COX-2 is an inducible enzyme un-
der stress conditions, such as inflammation.19,20 Asprin 
and ibuprofen are non-steroidal anti-inflammatory drugs 
(NSAIDs) which inhibit the metabolism of AA by COX 
enzymes to eicosanoids. These drugs have been used to 
prevent inflammation and recently been implicated as a 
potential therapeutic for neurodegenerative disease.21-23  
    Extensive literature searching has revealed the numer-
ous roles that metabolites of DHA and AA play in neural 
cells. In this paper we discuss the role of eicosanoids and 
docosanoids in sleep, memory, inflammation and neuro-
psychiatric disorders. We also briefly discuss how dietary 
alterations and drug therapy may influence their actions.  
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Figure 2. Overview of the actions of eicosanoids and docosanoids in sleep induction, memory formation and inflammation 
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Figure 1. Similarity of brain grey matter PUFA in three differ-
ent mammalian species 
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ESSENTIAL FATTY ACID FORMATION, INTE-
GRATION IN NEURONAL TISSUE AND ME-
TABOLISM 
Alpha-linolenic acid and linoleic acid are EFA and the 
precursors of the longer chain PUFA eicosapentaenoic 
acid (EPA) and DHA, and AA, respectively. The rate of 
conversion of dietary ALA to DHA in the body is very 
low.24 The rate of conversion of LA to AA has been diffi-
cult to determine although some sources state it to be less 
than 5% which is as much as 10x greater than ALA to 
DHA conversion.25  The rate of conversion of the EFA to 
their C20 and C22 fatty acid metabolites may be affected 
by age, stress, immune state and sex differences.25  Smok-
ing and alcohol also affect EFA conversion rate. Alcohol 
consumption significantly decreases levels of DHA in the 
feline brain and increases the levels of omega-6 derived 
PUFA.26  Smoking appears to have the opposite effect. 
Smoking has been found to increase the bioavailability of 
omega 3 PUFA. One possible mechanism is via increased 
absorption by the gut. However, it is more likely that this 
is achieved through a compensatory mechanism where the 
body increases endogenous transformation of omega 3 
PUFA to DHA. This compensates for the PUFA lost to 
oxidation by free radicals which are found in higher levels 
in smokers.27  
 
SLEEP 
Sleep is necessary for health and survival. Without suffi-
cient regular rest periods, mental and physical deficits 
arise including lack of concentration and motivation, 
muscle aches and visual anomalies. Sleep is characterised 
by cyclic phases that are measured through eye movement. 
Rapid eye movement sleep (REM) is a period where the 
brain is active and muscle tone is absent from the body; it 
is often associated with dreaming. In non-rapid eye move-
ment (NREM) sleep, cerebral activity is minimal and 
muscle tone is present. Postural changes are seen during 
this period.28 Prostaglandin D2 (PGD2) has been shown to 
play an important role in sleep regulation and memory 
formation (Fig. 3).  
    There is a circadian clock-dependent PGD2 fluctuation 
in cerebrospinal fluid. Rats exhibit a higher concentration 
of PGD2 during the day when they are sleeping than at 
night when they are awake.29  The brain upregulates PGD2 
production under sleep deprivation conditions in an at-
tempt to induce sleep. Results from animal experiments 
have exhibited a dose-dependent relationship between 
PGD2 and increased sleep time.30  Both NREM and REM 
were induced by intracerebroventricular infusions of 
PGD2 in mice, rats and monkeys.31 Likewise, inhibition of 
PGD2 formation through the introduction of selenium 
tetrachloride, a selective inhibitor of PGD2 synthase, in 
rats reduces NREM and REM sleep.32  Other experiments 
involving transgenic and knockout mice have supported 
PGD2’s role as a sleep inducer.33  
 
MEMORY AND LEARNING 
Simplistically, memory can be said to exist as two types, 
short term (STM) and long term memory (LTM). An 
“event” exists in the STM before it is stored as a LTM. 
This shift in memory storage is the result of neuronal re-
modelling in the brain. DHA has been shown to promote 
neurite growth and remodelling in hippocampal neurons 
which is important as the hippocampus is the main site for 
memory formation.16  
    Brain derived neurotrophic factor (BDNF) activity 
combined with PGE2 also regulate the synaptic plasticity. 
Specifically, it’s their actions which induce long-term 
potentiation (LTP). BDNF is a potent trophic factor in the 
brain.34 Synthesis of BDNF is induced by prostaglandins 
(Fig. 4). 
    In vitro experiments with mouse astrocyte cells shows 
PGE2 and PGD2 stimulate both nerve growth factor and 
BDNF production.35 Kesslack et al. and Mizuno et al. 
found that BDNF was elevated in the hippocampus of 
tested rats that learned a spatial memory task.36,37 It has 
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Figure 3. Scheme outlining the formation of PGD2 from AA 
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Figure 4. Scheme depicting role of eicosanoids in memory 
formation  
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also been documented that animals exhibit learning diffi-
culties when BDNF is reduced. This occurs through 
BDNF modulation of synapsin I, growth associated pro-
tein 43 (GAP-43) and cyclic AMP response element-
binding protein (CREB). Synapsin I action mediates ax-
onal growth and neurotransmitter (NT) release. GAP-43 
performs many of the same actions as synapsin I. CREB 
involvement in BDNF action is related to synaptic plastic-
ity after neuronal insult. BDNF receptor tyrosine kinase 
receptor B (trkB) also plays an important role in mem-
ory.38 Spatial learning induces phosphorylation of the 
receptor.  
    Modification at several sites in the memory signalling 
cascade has supported the theory that PUFA are important 
for memory. Rodent experiments showed that BDNF was 
important, not only for memory formation, but also for 
retention. 
1. n–3 PUFA deficiency impairs hippocampal-
dependent learning and memory39, 40 
2. PLA2 - inhibition in rat hippocampus impairs 
STM and LTM41 
3. Broad spectrum cyclooxygenase inhibitor - im-
pairs LTP and spatial learning capacity in rats23 
4. COX-2 - selective inhibitors NS392 and nimesu-
lide reduce LTP. This can be restored by the ad-
dition of PGE242 
5. BDNF - reduction through genetic manipulation 
of BDNF gene produced mice that exhibit learn-
ing difficulties43 
6. TrkB - inhibition of tyrosine kinase activity in 
rats delays memory acquisition38 
 
NEUROINFLAMMATION  
Inflammation involves the coordination of several mo-
lecular events whose purpose is to protect the affected 
tissue from damage. This is usually characterised by a 
physical change in an affected tissue, including heat, col-
our (red), swelling, pain and tenderness. Functional 
anomalies may also be attributed to inflammation in some 
cases. Neuroinflammation can be associated with both 
neurological injury and neurological disease. Neurologi-
cal injury can be brought about through invasive injury of 
the neural tissue, neurotoxins, bacterial or viral infiltration 
of the neural tissue or ischemia-reperfusion (IR) injury.44 
Alzheimer’s disease (AD), multiple sclerosis (MS) and 
epilepsy are all diseases with neuroinflammatory charac-
teristics.19 Beta-amyloid plaques and neurofibrillary tan-
gles are characteristic of AD and are the likely cause of 
the associated neuroinflammation. Long-term treatment 
with anti-inflammatory drugs has been shown to (a) re-
duce the risk of developing AD, (b) delay its onset and (c) 
slow its progression most probably through preventing or 
reducing chronic inflammation.45 
    Shortly after an insult to neural tissue, a rapid cascade 
of molecular events takes place to initially potentiate and 
then, in most cases, reduce the inflammatory response 
(Fig. 5). This begins with the migration of microglial cells 
and adhesion of leukocytes to the affected site. Microglial 
cells are responsible for the production of many cytokines, 
including tumour necrosis factor-α (TNF-α) and inter-
leukin-1β (IL-1β), and chemokines as well as vascular 
cell adhesion molecule-1 (VCAM-1) and intracellular cell 
adhesion molecule-1 (ICAM-1). The consequence of this 
increase in cytokine and chemokine production is a 
widely observed increase in PLA2 activity.46 Inflamma-
tion induced through bacterial lipopolysaccharide (LPS) 
infusion increases secretory PLA2A (sPLA IIA) activity, 
which is a non-selective phospholipase that hydrolyses 
both AA and DHA. Ca2+ influx associated with IR also 
stimulates PLA2 activity leading to an increase in free AA 
and/or DHA.46,47 Increases of PLA2 activity have also 
been determined through measurement of free fatty acids 
(FFA) in cerebrospinal fluid (CSF) following neural 
trauma. For up to 48 hours following traumatic brain in-
jury (TBI), levels of AA, DHA, LA and ALA are all sig-
nificantly elevated in CSF. The concentration of these 
FFA normalise around 96 hours after the initial injury. 
Further analysis of the data showed a correlation between 
the severity of the TBI with the level of FFA in the CSF.48 
    Following neural injury, the prostaglandins released are 
generally classed as exhibiting pro-inflammatory effects. 
Leukotrienes and thromboxanes elicit a vascular response 
(both are potent vasoconstrictors). Stroke results in an 
increase in both 5-LOX activity and leukotriene levels.49 
Other actions of leukotrienes include mediating chemo-
taxis of leukocytes and disruption of the blood brain bar-
rier.  They also increase free radical production as well as 
potentiating cytokine production.22 
    Lipoxins, also derived from AA, promote resolution of 
inflammation through a G-protein-coupled receptor lead-
ing to expression of a cytokine signalling inhibitor 
(SOCS-2).50 Mice deficient in SOCS-2 demonstrate un-
controlled production of pro-inflammatory cytokines and 
increased mortality. In addition to lipoxin, resolvins and 
neuroprotectins (from DHA) are also produced in the 
brain to counteract and resolve neuroinflammation. This 
is critical to ensure that the inflammatory response does 
not overwhelm the brain and cause excessive damage. 
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Figure 5. Scheme showing the role of eicosanoids and doco-
sanoids in neuroinflammation 
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These DHA-derived molecules are collectively known as 
docosanoids. A recent study by Michael-Titus and col-
leagues found that omega 3 fatty acids improve recovery 
after spinal cord injury.51 Rats injected with ALA and 
DHA three minutes after injury showed a significant in-
crease in locomotor performance and neuroprotection 
compared with AA-injected rats. In fact, this omega-6 
fatty acid appeared to potentiate damage in spinal cord 
injury when injected post-injury. Resolvin-type messen-
gers (17S-DHA) down-regulate the microglia produced 
cytokines TNF-α and IL-1β. Neuroprotectin D1 (10, 17S-
docosatriene, NPD1) also down-regulates cytokine pro-
duction.46  
    In conjunction with this, NPD1 generates several mes-
sengers to mediate an anti-inflammatory response44:  
1. Reduces NF-κB activation. NF-κB is a regulator of 
gene transcription of pro-inflammatory mediators.52 
2. Down-regulates COX-2 thus inhibiting the produc-
tion of pro-inflammatory AA derived eicosanoids. 
3. Reduces pro-apoptotic Bcl-2 family members, Bax, 
Bad (apoptotic regulators). 
4. Increases anti-apoptotic Bcl-2 and Bcl-xL (apoptotic 
regulators). 
5. Inhibition of neuronal cell death through reduction 
in caspase activation (mediator of apoptosis).12 
 
OXIDATIVE STRESS 
Reactive oxygen species (ROS) and reactive nitrogen 
species (RNS), commonly referred to as free radicals, are 
constitutively present in the body at low levels. Oxidative 
stress is a state in which the production of free radicals 
greatly increases to the point where the intracellular 
mechanisms which render the ROS harmless are over-
whelmed leaving the potential for the damage caused by 
the ROS to propagate. Regulating free radical production 
are several enzymes, including superoxide dismutase and 
catalase and antioxidants such as alpha-tocopherol. Free 
radicals can damage nucleic acids, protein and lipids.  
Alterations made to proteins, including enzymes, may 
lead to dysfunction and an increased susceptibility for 
proteolysis. DNA damage has deleterious effects as it has 
the potential for mutagenic replication. Lipid oxidation 
occurs when ROS and RNS attack bonds within the fatty 
acids. This oxidation propagates to other bonds along the 
fatty acid and to surrounding fatty acids. This is a concern 
especially in neural tissue as it contains a high proportion 
of PUFA. Free radical production does not always have a 
negative impact on the body. Higher organisms have in-
corporated free radicals into physiological signal cascades, 
for example, control of ventilation and vascular tone.53 
    With reference to neuroinflammation, ROS can be pro-
duced by two means. The first is by leukocytes that ac-
cumulate near the inflamed region. There is also some 
evidence for calcium (Ca2+) induced production of ROS. 
These ROS have the potential to damage intracellular 
components including the mitochondria. This can lead to 
an even greater increase in ROS through interference in 
the electron transport chain caused by damage to electron 
carriers. The free radicals produced by this damage in-
clude superoxide (O2•-), peroxide (H2O2) and hydroxyl 
(OH•) radicals. This is particularly relevant to IR injury. 
In the ischemic phase, oxygen and glucose deprivation 
cause an influx of Ca2+ which induces production of ROS. 
The reperfusion phase sees the restoration of blood flow 
that places further stress on the ROS defence system. 
Novel research conducted by Marchesalli and colleagues 
showed that NPD1 and 17R-resolvins reduced leukocyte 
infiltration attributed to IR injury in a mouse stroke 
model.54  
    DHA attenuation of oxidative stress has also been 
demonstrated in a TBI rat model.55 Synaptic dysfunction 
and cognitive impairment are attributed to TBI. One of 
the causes of this apart from the insult itself is an increase 
in ROS degradation of membrane phospholipids. Al-
though the exact mechanism is not known, rats on a fish 
oil supplemented diet displayed a significantly lower lev-
els of oxidative damage compared with control rats.55 
Lipid peroxidation has also been implicated in neurode-
generative disease. This may be related to alterations in 
membrane fluidity and damage to membrane transporters 
that result from oxidation.56  Abnormalities in intracellu-
lar lipid signalling may also be a consequence of oxida-
tive damage.  
    In some cases, cell function ceases due to overwhelm-
ing damage from free radical attack. Each cell has a dam-
age “threshold” level. If this is not reached then the cell 
will be repaired. If the extent of the damage is too great 
for repair, a cascade of intracellular events will unfold to 
induce apoptosis.  Mitochondrial mediated apoptosis oc-
curs via the mobilization of cytochrome c from the inner 
mitochondrial membrane via the Bax protein.57 This is 
facilitated by ROS.  With increased amounts of cyto-
chrome c released there is a higher probability of subse-
quent activation of caspases-9 and -3. This increases the 
likelihood of apoptosis of dopaminergic neurons. Cas-
pase-3 activation is reduced in an environment where 
omega-3 PUFA are in abundance. Neuro 2A cells en-
riched with phosphatidylserine, which is high in DHA, 
were shown to have decreased levels of apoptotic cell 
death, induced by deprivation of serum.58  This finding 
has important implications for neurodegenerative diseases 
which result from anomalies in programmed cell death.  
 
DEPRESSION AND OTHER NEUROPSYCHIAT-
RIC DISORDERS  
In the past studying the causes of neuropsychiatric disor-
ders has proved difficult due to the broad spectrum of 
symptoms and the difficulty of accurate diagnosis. Neu-
ropsychiatric disorders are thought to result from a com-
bination of genetic and environmental stimuli (Figure 6). 
Dietary PUFA intake has been implicated as being asso-
ciated with many neuropsychiatric disorders including 
depression, schizophrenia, AD, Attention Deficit Hyper-
activity Disorder (ADHD), dyslexia and autism.25,59  In 
conjunction with inadequate dietary intake, abnormalities 
in membrane phospholipid metabolism are also thought to 
cause or potentiate neuropsychiatric disease.25 
    Although the pathogenesis of depression is not well 
defined there is a surprisingly wide range of therapies and 
pharmaceuticals available for treatment. This can be at-
tributed to the serendipitous discovery of anti-depressant 
medication in the 20th century. It is now known that NT 
release, brain glucose metabolism, AA metabolism, pro-
inflammatory cytokines, BDNF and neuronal atrophy are 
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all associated with depression.60  Several classes of anti-
depressants specifically inhibit reuptake of the NTs sero-
tonin and noradrenaline in the brain to increase the 
amount available for receptor binding.61  It has been sug-
gested that depression is associated with an immune re-
sponse. As outlined above (see neuroinflammation), the 
release of pro-inflammatory cytokines is seen in neuroin-
flammation. Tricyclic anti-depressants inhibit cytokine 
release.  TNF-α, IL-1β and IL-6 have all been shown to 
decrease with administration of anti-depressants.62 TGF-
β1 and IL-12 have also been shown to decrease with 
treatment.63 Furthermore it has been noted that patients 
undergoing certain treatments which require cytokine 
administration, such as cancer and hepatitis C therapies, 
become symptomatic for depression.64  
    Impairment of neurotrophic mechanisms is a very ac-
tive avenue of neuropsychiatric disorder research. 
Changes in neuronal plasticity are of particular interest. It 
appears that variations in the levels of CREB and BDNF 
are related to the development of depression.  Brain ex-
pression levels of BDNF are influenced by environmental 
states, such as stress, exercise and diet. Stress increases 
glucocorticoid levels which reduce BDNF levels.61 
Chronic administration of antidepressants can not only 
normalise BDNF in the brain, but also increase the ex-
pression of the BDNF receptor trkB.61,65-67 Additionally 
pre-administration of anti-depressants prevents stress-
induced decrease in BDNF.68 It has also been hypothe-
sised that chronic stress-induced depression may result in 
neuronal atrophy and death. Theoretically, given the neu-
rotrophic effects of BDNF in mediating neuronal growth 
and synaptic plasticity, BDNF could act to reverse this. 
As it is not yet possible to measure BDNF in brain tissue 
of living human sufferers, a novel study introduced the 
idea of a possible correlation between serum BDNF levels 
and degree of depression. The treatment group composed 
of depression patients treated with antidepressants had 
significantly higher levels of BDNF compared with de-
pression patients with no treatment. They also found a 
correlation between BDNF levels and the degree of sever-
ity of depression in all patients.65 This is significant as it 
introduces the possibility for clinical molecular marker 
for depression. 
    BDNF expression is also partly mediated by CREB 
(see Fig. 6). There is a strong correlation between BDNF 
and CREB region specific expression in the brain. 
Chronic administration of anti-depressants upregulates 
CREB.68 Post-mortem examination of patients taking an-
tidepressants at time of death identified increased levels 
of temporal cortex CREB compared with those not on 
medication. It appears that the effect CREB has on de-
pression is not entirely due to an overall increase in 
CREB as some antidepressants reduce CREB in some 
parts of the brain and achieve the same effect.69 This sug-
gests that the role of CREB in depression is region spe-
cific. The mechanisms involved in the increase in CREB 
production by antidepressants have been reviewed by 
Vaidya and Duman.68  
    Ultimately, increased activation of CREB leads to in-
creased levels of BDNF resulting in neurotrophic effects 
including increased neuronal survival and function, and 
changes in structural plasticity. Interestingly, BDNF lev-
els can be increased by exercise and specific dietary com-
ponents such as omega 3 PUFA and decreased with a diet 
containing saturated fat and refined sugar.70-72 One study 
in rats consuming a diet high in saturated fat and refined 
sugar showed decreased level of BDNF mRNA and pro-
tein in the hippocampus.72 This reduction in BDNF was 
associated with impairment in spatial learning ability. 
This is a significant finding as exercise and dietary 
changes may be a safer alternative treatment to drugs 
when treating mild cases of depression, as they will not 
produce unwanted side effects. 
    Recent data in rats from Rapoport’s group revealed that 
the drugs commonly used to treat bipolar disorder, lithium, 
carbamazapine and valproic acid, significantly reduce AA 
turnover in the brain.73-75 This new information reveals 
the possibility of another explanation for the benefit seen 
from using omega 3 PUFA in mood disorders, given that 
the omega 3 PUFA competitively inhibit the metabolism 
of AA to eicosanoids and leukotrienes. Rats treated with 
lithium and carbamazapine demonstrated a reduced turn-
over of AA, but not DHA, in brain phospholipids and 
decreased mRNA, protein levels and enzyme activity of a 
cytosolic phospholipase A2, which is AA-specific.74,75  
This treatment also reduced the brain concentration of 
prostaglandin E2, a product of the COX pathway pre-
sumably due to reduced release of AA from the phosphol-
ipids.76 It is possible that EPA is effective in depression 
through its ability to inhibit COX activity, although the 
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Figure 6. Overview of the actions of the role of CREB in depression. 
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levels of EPA in the brain phospholipids are very low. 
The same group showed that another drug used in treating 
bipolar disorder, valproic acid, also reduced AA turnover 
in the brain but by a different mechanism, namely the 
inhibition of the formation of arachidonoyl CoA.77  It is of 
interest that two further papers from this group demon-
strate effects of chronic lithium on the elevation of brain 
glucose metabolism and on dopamine D2 receptor-
initiated signalling, via effects on AA turnover in the 
brain.78, 79  In addition to these findings, it has been shown 
that AA metabolism to eicosanoids in the brain is in-
creased by a dietary deficiency of omega 3 PUFA. Rats 
fed an omega 3 PUFA deficient diet for 15 weeks showed, 
as expected, decreased DHA in the frontal cortex and 
alterations in expression of enzymes related to AA me-
tabolism. Rao et al. showed that PLA2, iPLA2 and COX-1 
expression decreased while cPLA2, sPLA2 and COX-2 
expression increased.80 There was also a decrease in the 
expression of BDNF, CREB and p38 mitogen-activated 
protein kinase (MAPK) activity.81 Furthermore in vitro 
administration of DHA to astrocytes induced BDNF ex-
pression. This could be blocked by a p38 MAPK inhibitor 
leading to the conclusion that p38 MAPK is an important 
regulator of BDNF expression.81 In contrast, dietary sup-
plementation with omega 3 PUFA normalizes BDNF lev-
els that are reduced with brain injury. As expected down-
stream signalling effectors, synapsin I and CREB, also 
decreased with brain insult and were restored by dietary 
omega-3 supplementation.55 
An alternative theory to the cause of depression involves 
the possible decrease in membrane integrity. Reduction in 
the amount of DHA in a cell membrane will decrease 
membrane fluidity.82,83 This may lead to abnormal cellular 
functions as changes in membrane fluidity may impair 
receptor activation and function, ion channel function, 
production of secondary messengers, enzyme activity, 
signal transmission, gene expression and secretion of neu-
rotransmitters. 
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